University of California at San Francisco — San Francisco, California

University of California at San Francisco is a clinical research site located in San Francisco, California, United States 94143.

Crixeo Clinical Trials Trust Score: 85/100 (GOOD). This profile has not yet been claimed by the site owner.

University of California at San Francisco has participated in 158 clinical trials with 23 currently active.

Therapeutic areas: Asthma, HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms.

Sponsors: Milton S. Hershey Medical Center, Seagen Inc., Tularik.

Is this your site?

Is this your site? Claim your profile and control the information sponsors and patients see.

Other research sites in San Francisco

Browse all research sites in California · View every site in San Francisco

Sponsor Feasibility Report

Trust Score: 85/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for University of California at San Francisco?

University of California at San Francisco has a Crixeo Trust Score of 85/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has University of California at San Francisco conducted?

University of California at San Francisco has 158 clinical trials on record, with 23 currently active. Their work covers Asthma, HER2 Positive Breast Neoplasms, Hormone Receptor Positive Breast Neoplasms.

Is University of California at San Francisco accredited by Crixeo Clinical Trials?

University of California at San Francisco has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about University of California at San Francisco?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.